A phase I trial (NCT01109095) of HER2-targeted, CMV-specific CAR-T cells in progressive HER2-positive GBM demonstrated safety and clinical benefit in approximately one-third of patients, with some achieving durable responses (Ahmed et al. 2015). The gene discussed is ERBB2; the disease is glioblastoma.